Unassociated Document

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
 
Date of Report
(Date of earliest event reported): January 11, 2010
 
 
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Delaware
001-15281
76-0233274
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
2408 Timberloch Place, Suite B-7
The Woodlands, Texas  77380
(Address of principal
executive offices
and zip code)
 
(281) 719-3400
(Registrant’s telephone
number, including area
code)
  


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

o           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 8.01  Other Events.
 
On January 11, 2010, Repros Therapeutics Inc. (the “Company”) issued a press release titled “Repros Shelf Registrations of Stock are Effective.”  The press release also contained an update on the Company's various development programs.  A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01  Financial Statements and Exhibits.
 
(d)  Exhibits.
 
Exhibit
Number
 
Description
99.1
 Press Release dated January 11, 2010 
                                        
 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  Repros Therapeutics Inc.  
     
Date:  January 11, 2010    
       
 
By:
/s/ Joseph S. Podolski
  
   
Joseph S. Podolski
 
   
President and Chief Executive Officer
  
       
 
 
 
 
 
EXHIBIT INDEX
 
Exhibit
Number
 
Description
99.1
 Press Release dated January 11, 2010